to combat the disease," said Picker.
"Our vaccine mobilised a T-cell response that was able to overtake the SIV invaders in 50 per cent of the cases treated. Moreover, in those cases with a positive response, our testing suggests SIV was banished from the host. We are hopeful that pairing our modified CMV vector with HIV will lead to a similar result in humans," said Picker.
The study was published in the journal Nature.